Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash from Operations: 2019-2025

Historic Cash from Operations for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$109.6 million.

  • BridgeBio Pharma's Cash from Operations rose 39.32% to -$109.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$584.8 million, marking a year-over-year decrease of 29.90%. This contributed to the annual value of -$520.7 million for FY2024, which is 1.33% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Cash from Operations of -$109.6 million as of Q3 2025, which was down 35.81% from -$80.7 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Cash from Operations ranged from a high of $74.7 million in Q2 2024 and a low of -$219.5 million during Q1 2024.
  • Over the past 3 years, BridgeBio Pharma's median Cash from Operations value was -$144.3 million (recorded in 2023), while the average stood at -$130.7 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first slumped by 272.22% in 2023, then soared by 165.90% in 2024.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Cash from Operations stood at -$133.9 million in 2021, then spiked by 30.36% to -$93.2 million in 2022, then plummeted by 33.86% to -$124.8 million in 2023, then tumbled by 56.49% to -$195.3 million in 2024, then surged by 39.32% to -$109.6 million in 2025.
  • Its Cash from Operations stands at -$109.6 million for Q3 2025, versus -$80.7 million for Q2 2025 and -$199.2 million for Q1 2025.